County reports more than 400,000 new infections but experts suspect figures are gross underestimate
Covid-19 deaths surged past 4,000 for the first time in India on Saturday in one of the world’s worst outbreaks.
India reported a national record of 4,187 new deaths on Saturday.
Continue reading...Health commissioner says plan is to reduce hospitalisation and tackle long-term impact of Covid
Three Covid medicines with the potential to “change the course” of the pandemic will be authorised for mass production and use in the EU by October under a European Commission plan.
Stella Kyriakides, the commissioner for health, said such a move would reduce hospitalisation and tackle the long-term impact of Covid, with one in 10 people reporting symptoms 12 weeks after infection.
Continue reading...Analysis: Joe Biden’s support for idea is vital but it won’t happen without backing of other rich nations
It was a “seismic decision” by Joe Biden, the US president, say campaigners who have fought for the demolition of patent protection on vaccines and drugs for decades. The US administration has amazed supporters and critics alike by throwing its considerable weight behind the pleas of South Africa, India and about 100 developing countries at the World Trade Organization to overturn patents on Covid vaccines in the interests of getting more of them, more cheaply and faster, to huge populations in need.
Patents preserve the profits of the multinational companies that make drugs and vaccines. They make it illegal for up to 20 years for manufacturers of generic medicines to turn out cheap copycat versions. In this pandemic where, as the World Health Organization says, no one is safe until everyone is safe, there is a powerful moral case for ditching them.
Continue reading...Pascal Soriot says firm is doing its best to produce more and ‘should be proud of what we did in the world’
AstraZeneca’s chief executive, Pascal Soriot, has mounted a robust defence of the drugmaker’s Covid-19 vaccine efforts, and said the business should be proud of what it has done for the world and is doing its “very best” to produce more, as the company faces legal action from the EU over delivery shortfalls, and shipments to poorer countries have also been delayed.
The company generated $275m (£197m) in revenues from the Covid vaccine it developed with Oxford University in the first three months of the year and shipped 48m doses to 120 countries through the global vaccine-sharing initiative Covax, 80% of which went to low and middle-income countries. In total, it has supplied more than 300m vaccine doses to more than 165 countries so far this year.
Continue reading...Firm says it will ‘strongly defend itself’ against claim it breached agreement to supply Covid jab
AstraZeneca said it would “strongly defend itself in court” and highlighted its supply of 50m Covid vaccine doses to European countries as Brussels launched legal action against the pharmaceutical company over delivery shortfalls.
The Anglo-Swedish firm said it regretted the decision by the European commission to start a legal case over alleged breaches of an advance purchase agreement.
Continue reading...Commission move causes concern about bringing case against key supplier of Covid vaccines
EU capitals have been asked by the European commission to back legal action against AstraZeneca by the end of the week over an alleged breach of its contractual obligations to supply member states with its Covid vaccine.
At a meeting with commission officials on Wednesday, diplomats from some member states raised concerns about the wisdom of the move, warning against rushing into a decision that might further undermine confidence in the vaccine.
Continue reading...Only a fifth of Oxford/AstraZeneca doses expected by May delivered as export bans, hoarding and supply shortages bite
The global vaccine-sharing initiative Covax has so far delivered about one in five of the Oxford/AstraZeneca doses it estimated would arrive in countries by May, according to a Guardian analysis, starkly illustrating the cost of export bans, hoarding and supply shortages for a scheme that represents a key lifeline for many in the developing world.
The organisations that run Covax had predicted countries would receive fewer vaccines than expected after the Indian government restricted exports from its largest manufacturer in response to a catastrophic second wave there, but the figures reveal the shortfall to be severe, leaving many governments scrambling to secure doses elsewhere.
Continue reading...Fear of third wave and new variants as sub-Saharan vaccine distribution is dogged by supply disruption
Millions of healthcare workers in sub-Saharan Africa continue to risk their lives to fight Covid-19 as authorities across the continent struggle to obtain and distribute vaccines to frontline medical staff.
Though hundreds of millions of people in western nations are now protected from the virus, doctors, nurses and others on the frontline of the fight against Covid in Africa will have to wait months, or even years, for a vaccine.
Continue reading...EMA says four serious cases reported, one fatal, and also expands inquiry into AstraZeneca vaccine
The EU’s drug regulator is reviewing reports of rare blood clots in four people who received Johnson & Johnson’s Covid-19 vaccine and has expanded its inquiry into AstraZeneca’s shot to include reports of a bleeding condition.
Of the four serious cases of clotting and low platelets, three occurred in the US during the rollout of J&J’s vaccine from its Janssen pharmaceuticals unit, the European Medicines Agency (EMA) said on Friday, adding that one person had died and one case was reported in a clinical trial. It was the first news of EMA’s inquiry into the J&J vaccine.
Continue reading...Downing Street will not confirm or deny report that more than 700,000 Covid jabs were sent after EU blocked export
British ministers and officials did not deny that more than 700,000 shots of the AstraZeneca vaccine were secretly dispatched from the UK to Australia a few weeks ago as the EU blocked the drug’s export.
The Sydney Morning Herald reported that 717,000 AstraZeneca doses were dispatched in late February and March from the company’s British operations – also during a period when the EU was demanding the vaccine from the UK.
Continue reading...Despite scientific advice to continue getting the jab, answers about fatal blood clots are urgently needed
Vaccines have side-effects, as do all medicines. Most often, jabs cause sore arms, a headache or a bit of nausea – none of which would be very significant when weighed against the toll of a serious virus such as Covid-19.
But sometimes the risk-benefit calculation may look less simple, as in the case of Oxford/AstraZeneca’s Covid jab and cerebral venous sinus thrombosis (CVST), the blood clots in the brain that have led to fatalities in the UK and Europe.
Continue reading...Findings based on two doses three weeks apart are first to show shot remains effective for many months
The coronavirus vaccine developed by Pfizer and its German partner BioNTech protects against symptomatic Covid for up to six months, an updated analysis of clinical trial data has found.
In a statement released on Thursday, the companies reported efficacy of 91.3% against any symptoms of the disease in participants assessed up to six months after their second shot. The level of protection is only marginally lower than the 95% achieved soon after vaccination.
Continue reading...Immunisation panel says there is ‘substantial uncertainty about the benefit’ of the vaccine given risk of rare type of blood clot
Canada on Monday suspended the use of the Oxford/AstraZeneca coronavirus vaccine for people under 55 following concerns it might be linked to rare blood clots.
The pause was recommended by the National Advisory Committee on Immunization for safety reasons. The Canadian provinces, which administer health in the country, announced the suspension on Monday.
Continue reading...Serum Institute boss Adar Poonawalla has rented a Mayfair mansion for £50,000 a week
The AstraZeneca vaccine has made Prof Sarah Gilbert – who led the Oxford team that created it – one of the UK’s most famous modern scientists and turned the Anglo-Swedish pharmaceutical company into a household name.
But almost half of all the AstraZeneca shots, destined for the arms of hundreds of millions of people around the world, are being produced by a 40-year-old Indian billionaire with a penchant for private jets and Picassos.
Continue reading...Newly accused of data manipulation by the US, AstraZeneca has faced unprecedented scrutiny over the past six months
It was billed as the vaccine to deliver the world from Covid. But over the last six months, AstraZeneca – whose jab was designed to save thousands of lives for no profit – has found itself stumbling along an extraordinarily rocky road, facing accusations over the efficacy, supply and side-effects of its vaccine from all quarters, and being kicked about like a political football.
This week, AstraZeneca faced unprecedented public criticism in the US from a high-level scientific body claiming the British-Swedish company massaged the data from its long-awaited trial there. And in Italy, military police entered a factory on behalf of the European commission investigating allegations of 29m hidden doses, said to be intended for shipment to the UK. The commission, which is demanding AstraZeneca supplies more jabs to Europe, meanwhile drew up regulations which could block vaccine exports to the UK.
Continue reading...Investigation is fresh sign of breakdown in relations between Brussels and Anglo-Swedish vaccine supplier
An AstraZeneca plant has come under investigation by the Italian police at the request of Brussels in a sign of the breakdown in relations between the Anglo-Swedish vaccine supplier and the EU.
Officers were sent into the facility in the town Anagni, east of Rome, on Saturday evening after the European commission contacted the Italian government with concerns.
Continue reading...Bloc expected to assess countries’ Covid vaccination coverage and record in facilitating exports to EU
The EU is expected to take into account the level of vaccination coverage in a country and its record in facilitating exports to the bloc when deciding on whether to prohibit individual vaccine shipments to the UK and elsewhere.
The revision of the export authorisation scheme, widening the criteria that will guide Brussels’ decisions on export requests, is due to be announced on Wednesday. EU leaders will then on Thursday discuss going further in controlling vaccine distribution when they meet by videoconference.
Continue reading...EMA says benefits outweigh risks but it is continuing to study possible link with very rare blood clotting disorder
Italy, France and several other countries will resume administering AstraZeneca jabs from Friday after Europe’s medicines regulator said the vaccine was “safe and effective” and its benefits outweighed its risks.
Germany and Portugal will resume on Monday, Spain and the Netherlands next week, while Sweden’s public health agency said it would take “a few days” to decide.
Continue reading...The Oxford/AstraZeneca coronavirus vaccine is 'safe and effective' and its benefits outweigh the risks, Europe’s medicines regulator has said. The director of the European Medicines Agency, Emer Cooke, said the agency’s safety committee had reached 'a clear scientific conclusion' and had not found that the vaccine was associated with an increase in the overall risk of blood clots
Continue reading...Parents whose only hope was finding foreign sponsorship or a clinical trial are now looking for homegrown breakthroughs
For three years, Vidya tried to find the cause of her son’s recurrent fevers and low cognitive development. When she found out, she was devastated.
Vineeth, 10, has an incurable illness – mucopolysaccharidosis type 2 – that affects his organs. Afflicting just one in a million, the enzyme-replacement medication that can help stop the illness getting any worse costs £100,000 a year, far beyond the reach of even a wealthier Indian parent.
Continue reading...